Antibiotic resistance in Bartonella bacilliformis clinical isolates from an endemic area of Peru

2.50
Hdl Handle:
http://hdl.handle.net/10757/579762
Title:
Antibiotic resistance in Bartonella bacilliformis clinical isolates from an endemic area of Peru
Authors:
Silva Caso, Wilmer; J. Ruiz; Del Valle Mendoza, Juana; Pons, Maria J ( 0000-0001-8384-2315 )
Citation:
Silva-Caso W, Pons MJ, Ruiz J, del Valle-Mendoza J, Antibiotic resistance in Bartonella bacilliformis clinical isolates from an endemic area of Peru, Journal of Global Antimicrobial Resistance (2010), http://dx.doi.org/10.1016/j.jgar.2015.05.004
Publisher:
Elsevier B.V.
Journal:
Journal of Global Antimicrobial Resistance (J Glob Antimicrob Resist)
Issue Date:
15-Oct-2015
URI:
http://hdl.handle.net/10757/579762
DOI:
10.1016/j.jgar.2015.05.004
Additional Links:
http://www.jgaronline.com/article/S2213-7165(15)00060-0/references
Abstract:
Bartonella bacilliformis is a facultative, intracellular, aerobic, Gram-negative coccobacillus causing the so-called Carrión's disease, a human infection endemic to specific areas mainly inhabited by low-income communities of Peru but also present in other Andean communities. It is considered a truly neglected tropical disease and is transmitted through the bite of female sandflies of the genus Lutzomyia [1]. Carrión's disease has two different clinical presentations; an initial febrile and haemolytic anaemia phase, known as Oroya fever, which has a mortality rate ranging from 44% to 88% in untreated patients; and a second phase characterised by the development of dermal eruptions known as Peruvian wart [1,2]. 
Type:
info:eu-repo/semantics/article
Rights:
info:eu-repo/semantics/openAccess
Language:
eng
Keywords:
Bartonella bacilliformis; Endemic area; Perú
ISSN:
2213-7165

Full metadata record

DC FieldValue Language
dc.contributor.authorSilva Caso, Wilmeres_PE
dc.contributor.authorJ. Ruizes_PE
dc.contributor.authorDel Valle Mendoza, Juanaes_PE
dc.contributor.authorPons, Maria Jes_PE
dc.date.accessioned2015-10-15T16:55:06Zes_PE
dc.date.available2015-10-15T16:55:06Zes_PE
dc.date.issued2015-10-15es_PE
dc.identifier.citationSilva-Caso W, Pons MJ, Ruiz J, del Valle-Mendoza J, Antibiotic resistance in Bartonella bacilliformis clinical isolates from an endemic area of Peru, Journal of Global Antimicrobial Resistance (2010), http://dx.doi.org/10.1016/j.jgar.2015.05.004es_PE
dc.identifier.issn2213-7165es_PE
dc.identifier.doi10.1016/j.jgar.2015.05.004es_PE
dc.identifier.urihttp://hdl.handle.net/10757/579762es_PE
dc.description.abstractBartonella bacilliformis is a facultative, intracellular, aerobic, Gram-negative coccobacillus causing the so-called Carrión's disease, a human infection endemic to specific areas mainly inhabited by low-income communities of Peru but also present in other Andean communities. It is considered a truly neglected tropical disease and is transmitted through the bite of female sandflies of the genus Lutzomyia [1]. Carrión's disease has two different clinical presentations; an initial febrile and haemolytic anaemia phase, known as Oroya fever, which has a mortality rate ranging from 44% to 88% in untreated patients; and a second phase characterised by the development of dermal eruptions known as Peruvian wart [1,2]. eng
dc.formatapplication/pdfes_PE
dc.language.isoenges_PE
dc.publisherElsevier B.V.es_PE
dc.relation.urlhttp://www.jgaronline.com/article/S2213-7165(15)00060-0/referenceses_PE
dc.rightsinfo:eu-repo/semantics/openAccesses_PE
dc.sourceUniversidad Peruana de Ciencias Aplicadas (UPC)es_PE
dc.sourceRepositorio Académico - UPCes_PE
dc.subjectBartonella bacilliformises_PE
dc.subjectEndemic areaes_PE
dc.subjectPerúes_PE
dc.titleAntibiotic resistance in Bartonella bacilliformis clinical isolates from an endemic area of Perues_PE
dc.typeinfo:eu-repo/semantics/articlees_PE
dc.identifier.journalJournal of Global Antimicrobial Resistance (J Glob Antimicrob Resist)es_PE
dc.description.fundingThe study was supported by internal funds from the Universidad Peruana de Ciencias Aplicadas (Lima, Peru); by a grant from the Instituto de Salud Carlos III, Spain [PI11/00983], which included FEDER funds; by the UBS Optimus Foundation; and by Generalitat de Catalunya, Departament d’Universitats, Recerca i Societat de la Informació [2014 SGR 26]. MJP has received a postdoctoral fellowship from CONCYTEC/FONDECYT. JR has received a fellowship from the program I3 of the ISCIII [grant no. CES11/012].es_PE
dc.description.peer-reviewRevisión por pareses_PE
This item is licensed under a Creative Commons License
Creative Commons
All Items in UPC are protected by copyright, with all rights reserved, unless otherwise indicated.